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A B S T R A C T   
Background: Opioid use during pregnancy is a significant public health issue. The standard of care for treating 
opioid use disorder during pregnancy includes medications for opioid disorder (MOUD). However, tobacco use 
often goes unaddressed among pregnant women on MOUD. In 2018, our team received a National Institute on 
Drug Abuse (NIDA) funded R34 to conduct a three year-randomized trial to test the feasibility of a novel tobacco 
intervention for pregnant women receiving MOUD. 
Aims: The aims of this study are: (1) to determine the impact of the B-EPIC intervention on maternal tobacco use 
and stage of change; (2) to determine the impact of B-EPIC on tobacco-related maternal and infant health out-
comes including gestational age at birth, birthweight, NAS diagnosis and severity, and number of ear and res-
piratory infections during the first six months; (3) to compare healthcare utilization and costs incurred by 
pregnant patients that receive the B-EPIC intervention versus TAU. 
Methods: We plan to enroll 100 pregnant women on MOUD for this randomized controlled trial (B-EPIC inter-
vention n = 50 and treatment as usual n = 50). A major strength of this study is its wide range of health and 
economic outcomes assessed on mother, neonate and the infant. 
Conclusions: Despite the very high rates of smoking among pregnant women with OUD, there are few tobacco 
treatment interventions that have been tailored for this high - risk population. The overall goal of this study is to 
move towards a tobacco treatment standard for pregnant women receiving treatment for OUD.   
1. Introduction 
Opioid use and untreated opioid dependence (Diagnostic and Sta-
tistical Manual of Mental Disorder, 4th Edition, DSM 4) during preg-
nancy is a significant public health issue associated with complications 
such as intrauterine growth restriction, placental abruption, preterm 
delivery, cesarean delivery, and stillbirth [1]. Intravenous opioid use 
increases the risk of infectious diseases such as hepatitis C and endo-
carditis [2], which complicate pregnancy [3,4]. As opioid use in the U.S. 
has increased, there has been a dramatic increase in the prevalence of 
neonatal abstinence syndrome (NAS) [5]. From 2004 to 2014, the total 
healthcare costs covered by Medicaid for infants with NAS increased 
from $65.4 million to $462 million [6]. 
The standard of care for treating opioid use disorder (OUD) during 
pregnancy includes FDA-approved medication for opioid use disorder 
(MOUD; also known as medication assisted treatment), including 
methadone or buprenorphine. [7].According to the Substance Abuse 
and Mental Health Service Administration (SAMHSA), these medica-
tions help pregnant women stop injection drug use and reduce with-
drawal and cravings [8]. However, tobacco use often goes unaddressed, 
which is unfortunate because pregnant women in MOUD programs have 
high rates of smoking (88–95%) [9,10] and smoking is an independent 
risk factor for several maternal and infant adverse health outcomes [9]. 
For instance, smoking during pregnancy can lead to miscarriage [11], 
premature birth [12], and sudden infant death syndrome [13]. In 
addition to the general risks, smoking during pregnancy is associated 
with higher amounts of medication needed to treat NAS, longer duration 
of treatment, and longer hospital stays [14]. Smoking during pregnancy 
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also has adverse economic consequences for families and the healthcare 
system. Maternal smoking increases the risk admission to the neonatal 
intensive care unit (NICU) by 19% [15], which results in significant 
smoking-attributable hospital costs during the episode of delivery. 
Smoking cessation has immense benefits for women and their fam-
ilies over the long-term. Infants born to mothers who smoke during 
pregnancy are more likely to be readmitted to the hospital during their 
first year of life [16], more likely to experience asthma requiring 
medication use, and are more likely to use the emergency room [17]. 
Further, smoking increases the risk for several women’s health issues, 
including breast cancer [18], osteoporosis [19], and infertility [20]. 
Smoking cessation is particularly important for women with substance 
use disorders, because smoking has been associated with an increased 
risk of relapse [21]. 
Few tailored tobacco treatment interventions have been tested for 
pregnant women on MOUD. Across these studies, a small percentage of 
participants stopped smoking [10,22], indicating the need for a more 
intense, tailored intervention for this population. One study showed 
promise using an intervention that included contingency-behavioral 
incentives [23], but effects of contingency incentives often cease after 
the intervention period ends. Incentives are difficult to implement in 
real-world clinical practice as there is no current way to reimburse for 
them. Thus, there is a critical need to develop clinical care models that 
incorporate feasible and effective behavioral interventions for tobacco 
use among pregnant women receiving opioid use disorder treatment. 
In 2018, our team received a National Institute on Drug Abuse 
(NIDA) funded R34 to conduct a three year-randomized trial to test the 
feasibility of a novel tobacco intervention (Behavioral and Enhanced 
Perinatal Intervention for tobacco Cessation; B-EPIC) for pregnant 
women receiving comprehensive buprenorphine treatment for their 
OUD. The purpose of this paper is to present the B-EPIC study design, 
intervention and intervention framework, and data analysis plan. 
2. Methods 
2.1. Study aims 
The study aims are to: 
Aim 1. To determine the impact of the B-EPIC intervention on 
maternal tobacco use and stage of change [24] during and after preg-
nancy compared to the tobacco treatment as usual (TAU) control group 
among women with opioid dependence receiving MOUD. 
Hypothesis 1. The B-EPIC group will have a greater percentage of 
perinatal women who quit smoking, decrease number of cigarettes 
smoked per day, and/or increase their readiness to quit smoking 
compared to TAU. 
Aim 2. To determine the impact of B-EPIC on tobacco-related 
maternal and infant health outcomes including gestational age at 
birth, birthweight, NAS diagnosis and severity, and number of ear and 
respiratory infections during the first six months. 
Hypothesis 2. Women in the B-EPIC intervention will have a gesta-
tional period of at least 37 weeks and their infants will experience less 
severe NAS (e.g, number of days in the neonatal intensive care unit or 
total mg of morphine needed to treat NAS) and fewer associated child-
hood illnesses (e.g, frequency of ear and respiratory infections), and 
increased number of well-child visits compared to TAU. 
Aim 3: To compare healthcare utilization and costs incurred by 
pregnant patients that receive the B-EPIC intervention versus TAU, with 
estimates of the incremental cost-effectiveness of the B-EPIC 
intervention. 
Hypothesis 3. Infants of participants in B-EPIC will have fewer hos-
pitalizations and hospital days, as well as fewer NICU admissions, 
emergency department (ED) visits, and sick-child outpatient visits. As a 
secondary hypothesis, we will investigate whether infants also 
demonstrate greater adherence to the recommended well-child visits. 
Reduced healthcare utilization associated with B-EPIC will yield a 
favorable incremental cost-effectiveness ratio. 
2.2. Intervention framework 
We conducted two qualitative studies that provided the foundation 
for the theoretical framework used to guide B-EPIC. First, our team 
conducted a qualitative study to describe factors that contribute to 
successful maintenance of smoking cessation during the postpartum 
period among women who quit smoking during pregnancy (n = 11) 
(although they did not have OUD). Primary motivators and lifestyle 
characteristics of women who do not relapse to cigarette smoking [25] 
for at least 6 months were investigated. Women’s narratives described 
the process of postpartum smoking abstinence. Four themes emerged 
and provide the basis for the holistic theoretical model Smoking Cessation 
Model for Childbearing Women (Fig. 1): a) pregnancy is the primary 
motivator for change; b) changes in thought processes that promote quit 
attempts and help maintain abstinence; c) focus on healthy behaviors, 
which may serve as healthy coping skills/replacement smoking behav-
iors and prevention of smoking lapse/relapses; and d) child’s health as 
primary motivator for cessation [25]. 
Second, we conducted a qualitative study among pregnant women 
with opioid dependence (DSM 4) in an MOUD clinic who were being 
treated with buprenorphine (n = 22), to assess attitudes toward smoking 
cessation, facilitators and barriers to smoking cessation, and past ex-
periences with smoking cessation attempts [26]. The women reported: 
a) a desire to stop smoking for their health and the health of their baby, 
which was similar to the previous study and provided further support for 
the idea that smoking cessation interventions would be welcome by 
pregnant patients receiving MOUD; b) complex barriers to cessation, 
including the use of tobacco products to deal with chronic stress, which 
fits into the need to develop healthy coping and relapse prevention skills 
for stress; c) periodic nicotine abstinence in tobacco-free rehabilitation 
facilities and in prison, which supports that abstinence is feasible; and d) 
desire for intensive support for tobacco cessation, which suggested that 
the intervention would need regular follow-up and opportunities for 
supplemental help [22]. Lessons learned from these narrative accounts 
have been integrated into the Smoking Cessation Model [21] to inform 
the B-EPIC intervention, as shown in Fig 2. 
3. Study design 
3.1. Study setting and sample 
The goal is to enroll and randomize 100 pregnant women receiving 
MOUD treatment with buprenorphine for OUD. The study recruitment is 
ongoing at two sites in Lexington, Kentucky. Recruitment began at 
University of Kentucky Healthcare’s (UKHC) buprenorphine treatment 
program for pregnant women with OUD, and later expanded to include 
Baptist Health Lexington’s (BHL) similar prenatal buprenorphine MOUD 
program. 
3.2. Study eligibility 
Planned eligibility for this study included: 1) current diagnosis of 
opioid dependence (DSM 4) with participation in the UKHC integrated 
prenatal care and addiction treatment program with buprenorphine 
pharmacotherapy; 2) pregnant and less than 24 weeks gestation; 3) age 
18–49 years old; 4) diagnosis of current tobacco use disorder; and 5) 
ability to read or write in English. Women are excluded if they have 
current prisoner status, diagnosed current severe mental illness, or 
alcohol or sedative/hypnotic dependence that requires medical inter-
vention. Given recruitment challenges, two modifications were made to 
the eligibility criteria: 1) recruitment was expanded to include partici-
pants in the Baptist Health Lexington integrated prenatal care and 
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addiction treatment program with buprenorphine pharmacotherapy, 
and 2) participants of gestational age up to 32 weeks. 
4. Procedure 
4.1. Recruitment 
There are two methods of recruitment: 1) study flyers are posted in 
highly visible areas in the two MOUD clinics for pregnant/postpartum 
women and 2) in-person invitation by a research nurse. At an initial 
prenatal visit in the buprenorphine clinic, clinic staff determines pa-
tient’s smoking status. For all confirmed smokers, clinic staff assess their 
willingness to receive study information from a research nurse. If the 
patient is agreeable, a research nurse explains the purpose and proced-
ures of the study, and determines initial eligibility for participation. 
Women who are interested in participating and meet eligibility re-
quirements are then taken through the informed consent process by a 
research nurse prior to initiating any study procedures. 
4.2. Randomization 
Eligible participants are randomly assigned to one of two groups: 
TAU tobacco treatment (control group) or B-EPIC group (tobacco 
intervention) or. Participants are randomized to study group using SAS 
PLAN (SAS Institute, Inc) that incorporates a stratification procedure 
based on age (30+ verse less than 30). All participants continue to 
receive opioid dependence treatment with buprenorphine integrated 
with prenatal care, regardless of treatment assignment. 
4.3. Tobacco treatment as usual (TAU) 
Women enrolled in the TAU control group receive standard of care 
from their healthcare provider, which is the American College of Ob-
stetrics and Gynecology (ACOG) recommended 5 A’s approach [27] (see 
Table 2). This standard takes approximately 5–15 min and is offered by 
the healthcare provider at each prenatal and postpartum appointment. 
4.4. B-EPIC intervention 
Women enrolled in the intervention group will receive TAU plus B- 
EPIC, which includes four core components: 1) individualized tobacco 
treatment plus supplemental counseling providing intensive support, 2) 
change in maternal thought process and adoption of healthy behavior, in 
accordance with the findings from our previous qualitative work [25, 
26], 3) biomarker validation and feedback [28], and 4) pharmaco-
therapy targeted at tobacco cessation as needed. See Table 3 for a 
Fig. 1. Model guiding the B-EPIC intervention based on qualitative data collection  
Table 1 
Certified tobacco Treatment Specialists Core Competencies.   
1 Tobacco dependence knowledge  
2 Counseling and motivational interviewing skills  
3 Assessment skills  
4 Individualized treatment planning  
5 Pharmacotherapy knowledge  
6 Relapse prevention  
7 Competence in working with diverse population subgroups  
8 Referral resources for additional support  
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summary of the study visits and the components of each visit for the TAU 
and B-EPIC groups. The initial assessment for this intervention takes 60 
min, with follow-up sessions typically lasting 15–20 min. All sessions 
occur prior to or after pre-scheduled perinatal appointments. 
The intervention will be led by a research nurse who is certified as a 
certified tobacco treatment specialist (CTTS). A CTTS is a professional 
who possesses the skills, knowledge and training to provide effective, 
evidence-based interventions for tobacco dependence across a range of 
intensities. CTTS’s are trained in core competencies for the delivery of 
tobacco dependence treatment consistent with established evidence (see 
Table 1 for CTTS core competencies). Assessment, motivational coun-
seling, and treatment planning (for both cessation and relapse), which 
are tailored to the unique needs of tobacco users, are core skills used in 
the delivery of CTTS services. Based on the CTTS assessment, inter-
vention materials are tailored based on each woman’s individual rea-
sons for being interested in smoking cessation (Table 4). Further, in 
accordance with the model guiding this study, CTTS’s are trained to 
empower women to adopt a smoke-free home environment to support 
their cessation efforts and to avoid secondhand smoke exposure [25]. 
Perinatal Pharmacotherapy: According to the U.S. Preventive Ser-
vices Task Force, nicotine replacement therapy has not been sufficiently 
evaluated for safety or efficacy during pregnancy [29]. ACOG recom-
mends that nicotine replacement therapy be used during pregnancy only 
after a discussion of the risks of both continuing to smoke and of using 
nicotine replacement therapy, under close medical supervision, and 
with patients who express a strong desire to quit smoking [27]. The 
CTTS provides clear information about the pharmacotherapy options 
that are available (e.g, benefits, contraindications, and side effects) and 
will communicate with the participant’s obstetrician about participant’s 
interest in pharmacotherapy, if desired by the participant. 
5. Measures 
A major strength of this study is its wide range of health and eco-
nomic outcomes assessed on mother, neonate and the infant. 
Table 2 
ACOG’s 5 A’s treatment as usual.   
1. ASK the patient about smoking status at the 1st prenatal visit and follow-up with 
her at subsequent visits.  
2. ADVISE the patient who smokes to stop by providing advice to quit with 
information about the risks of continued smoking to the woman, fetus, and 
newborn.  
3. ASSESS the patient’s willingness to attempt to quit smoking at the time. Quitting 
advice, assessment, and motivational assistance should be offered at subsequent 
visits.  
4. ADVISE the patient who smokers to stop by providing advice to quit with 
information about the risks of continued smoking to the woman, fetus, and 
newborn.  
5. ASSESS the patient’s willingness to attempt to quit smoking at the time. Quitting 
advice, assessment, and motivational assistance should be offered at subsequent 
visits.  
Table 3 
Summary of study visits.  
Time points B-EPIC -Taking Action Treatment as Usual Outcomes Incentives 
Baseline (up to 32 
weeks)  
• ACOG recommended 5A’s conducted by healthcare provider  
• Individualized tobacco treatment sessions with CTTS (every month- 
minimum) plus supplemental counseling as desired (based on model, 
see Fig. 1)  
• Biomarker validation and feedback  
• CTTS will discuss pharmacotherapy with healthcare provider if desired 
by participant 
ACOG recommended 5A’s 
conducted by healthcare provider  
• Prenatal History  
• Demographics  
• Survey  
• Biomarkers 
$20 gift 
card 
3rd trimester 
(28–36.6 weeks) 
• Prenatal History  
• Survey  
• Biomarkers 
$20 gift 
card 
After Delivery of 
Baby (2–8.6 weeks)  
• Labor and Birth 
History  
• Newborn History  
• Survey  
• Biomarkers 
$40 gift 
card 
After Delivery of 
Baby (20–28.6 
weeks)  
• Maternal and Infant 
Outcomes  
• Survey  
• Biomarkers 
$40 gift 
card 
Note: American College of Obstetricians and Gynecologists (ACOG); Certified Tobacco Treatment Specialist (CTTS); if all four study visits are completed, participant 
receives an additional $20 gift card; Survey covers demographics, prenatal history, self-report tobacco use, nicotine dependence, secondhand smoke exposures, self- 
recall substance use, recovery capital, perceived stress, adverse childhood events, anxiety, and depression. 
Table 4 
B-EPIC intervention topicsa.   
• Impact of smoking on pregnancy/fetal health  
• Impact of smoking on neonatal abstinence syndrome  
• Smoking cessation and long-term sobriety  
• Impact of smoking on women’s health  
• Effects of secondhand smoke on children  
• Financial cost of smoking  
• Smoking and COVID-19  
a Information presented to participants is tailored based on their personal 
reasons for wanting to stop smoking. 
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5.1. Primary outcomes 
The primary outcomes for Aim 1 are smoking cessation, decrease in 
number of cigarettes smoked per day, and readiness to quit smoking. 
Smoking cessation is defined as a urine cotinine assay <100 ng/mL. 
Cotinine is a metabolite of nicotine and has a half-life of approximately 
9 h in pregnant women [30]. A commercial urine assay, NicAlert ®, with 
cut-off limits of urine cotinine levels is a valid assay to measures urine 
cotinine levels and to verify conventional cigarette use. Cigarettes per 
day is measured via self-report on a survey. Readiness to quit is 
measured using a ladder scale with ten options to indicate an in-
dividual’s readiness to quit smoking [24]. 
The primary outcomes for Aim 2 are gestational age at birth, birth-
weight, NAS diagnosis and severity, and number of ear and respiratory 
infections during the first 5–6 months of age. All these data will be 
collected via medical record review or by linking to Kentucky Medicaid 
claims data. Gestational age at birth is defined as age in weeks on de-
livery day, based on estimated weeks at first ultrasound. Birthweight is 
defined as the first infant weight on day of delivery in grams. NAS 
severity is determined based on the modified Finnegan Scale [31]. The 
International Statistical Classification of Diseases and Related Health 
Problems (typically abbreviated as ICD) diagnostic codes will be 
collected from well-child and sick visits and hospital admissions and 
re-admissions to determine ear and respiratory infections (e.g, tinnitus 
unspecified is code 388.30). 
The primary outcomes for Aim 3 are hospitalizations, hospital days, 
NICU days, ED visits and sick-child outpatient visits for infants. These 
data will be collected primarily from Kentucky Medicaid claims data, 
with supplementary information from the medical record (for non- 
Medicaid study participants). 
5.2. Data analysis 
Descriptive analysis, including means, standard deviations and fre-
quency distribution summarize all study outcomes. Baseline character-
istics between the intervention group and the control, and between 
those who complete the study and those who drop out will be examined 
for potential covariates. These comparisons will be done using t-sample 
t-tests, Mann-Whitney U tests, or chi-square tests of association, and 
significant outcomes will be used as covariates in the following analyses. 
Primary outcomes to be compared between treatment groups will 
include tobacco indicators, such as smoking and illicit drug use status 
(abstinence via urine cotinine) smoking frequency and readiness to quit 
(cigarettes per day and stages of change), and maternal-child measures 
(gestational age of birth, birthweight, NAS, NAS severity, early child-
hood respiratory and ear infections). The collected variables will include 
not only these primary outcomes and covariates, but also feasibility 
indicators, such as average number of sessions completed and satisfac-
tion ratings of the intervention by participants randomized to the 
intervention group. We will also make group comparisons between 
other variables that may affect maternal-child outcomes, including 
second hand smoke (SHS) exposure, infant feeding status at discharge 
(breastfeeding vs. formula), and number of people smoking in the home. 
The continuous outcomes for the first two study aims will be analyzed 
with a two-factor (group x time) repeated measures mixed model. 
Generalized estimating equation (GEE), analyses with an exchangeable 
correlation structure will assess for significant differences between 
groups and across time for categorical and dichotomous outcomes (e.g., 
preterm birth, NAS) using the SAS GENMOD procedure. The main ef-
fects of group and time and the interaction between them will be 
included in each model, and covariates will be added to control for 
group differences. As appropriate, post-hoc pairwise comparisons will 
be calculated using Fisher’s least significant difference procedure for 
mixed models and using contrast statements for GEE models. All ana-
lyses will be conducted using SAS 9.4 (SAS Institute, Inc) and considered 
significant at p ≤ 0.05. 
For Aim 3, the economic analysis will combine outcomes data from 
Aim 2 (gestational age, birthweight) with cost data (direct and indirect 
program costs, infant health services utilization) to assess incremental 
cost effectiveness from a health system/payer perspective. Direct pro-
gram costs will include personnel time directly associated with inter-
vention delivery, including logged staff time and travel, but also pro rata 
portions of supervision and office costs and any other costs that may be 
associated with care delivery (e.g. printed materials). Indirect program 
costs will include personnel time, materials, or facilities associated with 
general program development and operations. This will be derived from 
grant budgets and information supplied by community partners. Health 
services utilization (e.g. physician office visit, emergency department 
visit, hospitalization) will be costed out using average payment rates for 
these services, by age, gender and year (source: Medical Expenditure 
Panel Survey). Any facility usage (square feet) will be converted to an 
imputed rent amount, using local rental rates (per square foot) for office 
properties in the same zip code. This offers a conservative (high) esti-
mate of the cost of space and represents the opportunity cost of the 
space. Personnel time will be converted into monetary costs using 
actual wage rates available through grant budgets or Bureau of Labor 
Statistics (BLS) area wage surveys. To facilitate translation of our results 
to other settings while maintaining privacy, our publications will sum-
marize labor cost data by category (direct program, indirect program, 
participant) and subcategory (e.g. faculty, staff, participant), and 
include information on both time (in hours) and average hourly wage 
rates. 
The within-trial, incremental cost effectiveness ratio will be 
computed as the ratio of the (1) difference in costs (B-EPIC group minus 
TAU group) and (2) the difference in clinical outcomes. Separate esti-
mates will be generated for each outcome measure (gestational age, 
birthweight). We will also conduct sensitivity analyses where we 
dichotomize outcomes (preterm, low birth weight). All estimates of costs 
will be adjusted for inflation and transformed to net present value using 
an annual discount rate. The results of this exploratory economic anal-
ysis will provide critical preliminary data that will be used to estimate 
the statistical power for a larger future study. 
5.3. Sample size 
Sample size for this project was premised with a power of 0.8, alpha 
= 0.05 and medium effect sizes. These assumptions were based upon 
previous studies conducted with similar experimental designs and out-
comes. With at least 30 mother/baby dyads completing the study per 
group and an alpha level of 0.05, the power of the repeated measures 
analysis of variance F test to detect a significant main for group will be 
79%, assuming a medium effect size, while the power of the F tests to 
detect a significant main effect of time or group by time interaction will 
be at least 95%. In a preliminary study of this population by our group 
(EMPOWR), we found that 14% of pregnant women decreased their 
cigarette consumption between intake (typically during the second 
trimester) and the third trimester. While smoking cessation is the ulti-
mate goal of this intervention, prior research has demonstrated that 
cutting cigarette consumption below 8 cigarettes per day is a risk 
reduction strategy for preventing low birthweight, so we will consider 
outcomes of both successful cessation as well as reduction in con-
sumption for this project. Analysis of these power estimates indicates 
that 100 subjects (50 per group) completing the proposed study will be 
sufficient to detect significant main effects of treatment group. 
6. Discussion 
This study has several innovative features. First, the B-EPIC inter-
vention is based on a novel theoretical framework developed by the 
Principal Investigators based on previous qualitative work among 
pregnant and postpartum tobacco and opioid dependent women, 
including those receiving buprenorphine treatment. Second, this 
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feasibility study has the potential to lead to a larger, multi-site trial 
intervention, which if successful, would have the capacity to shift clin-
ical practice paradigms to give specific emphasis on tobacco use rather 
than letting it fall into general group discussions on illicit substance use 
and psychosocial issues. Current standard of care does not prioritize 
tobacco treatment for pregnant women with OUD. Due to time con-
straints on clinicians, and the complex issues facing many women with 
substance use disorders, tobacco often does not receive priority of 
attention. Third, we are conducting a comprehensive evaluation of this 
major public health issue, including a wide-range of maternal, neonatal, 
and infant health outcomes, as well as associated healthcare costs and 
cost effectiveness of the B-EPIC intervention. 
There is a high likelihood of adoption, scalability and sustainability 
of B-EPIC in clinical practice settings for two primary reasons. First, The 
B-EPIC intervention was designed to be integrated into programs 
providing comprehensive treatment for OUD, including buprenorphine, 
and across the country, there are a growing number of buprenorphine 
providers (e.g., over 111,000 providers who are waivered to provide 
buprenorphine) [32]. Second, the intervention relies on CTTS, who are 
providing billable services that are reimbursed from private and public 
insurers, and there are CTTS training programs available across the 
country in-person and via virtual platforms [33]. 
Limitations. This study also has several limitations. First, the validity 
of the FTND may vary across sex, gender and race/ethnicity [34,35]. 
Additionally, some healthcare providers have concerns that using urine 
cotinine to validate smoking status may their clinical relationship with 
their patients [36]. However, pregnant and postpartum women who 
smoked before or during pregnancy have reported that point-of-care 
cotinine testing had benefits, including encouraging conversations 
around tobacco cessation [36]. Further, in order to rigorously evaluate 
the impact of the intervention on smoking outcomes, it is necessary to 
verify smoking status. Previous research indicates that more than 25% of 
pregnant and postpartum women did not disclose tobacco use but had a 
positive urine cotinine screening [37]. 
7. Conclusion 
Smoking during pregnancy is a serious maternal child health issue. 
Despite the very high rates of smoking among pregnant women with 
OUD, there are few tobacco treatment interventions that have been 
tailored for this high - risk population. The overall goal of this study is to 
move towards a tobacco treatment standard for pregnant women 
receiving treatment for OUD. 
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